NGM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...

Stats
Today's Volume	263 031
Average Volume	315 455
Market Cap	86.85M
EPS	$-0.460
Earnings date	2023-08-03
Next earnings date	2023-11-01 ( $-0.400)
P/E	-0.530
ATR14	$0.0040 (0.38%)

Volume Correlation

Long: -0.46 (neutral)

Short: -0.52 (weak negative)

Signal:(33.448) Neutral

NGM Biopharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NGM Biopharmaceuticals Correlation - Currency/Commodity

0.25
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.43
( neutral )

NGM Biopharmaceuticals Financials

Annual	2022
Revenue:	$55.33M
Gross Profit:	$55.33M (100.00%)
EPS:	$-1.990

Q2	2023
Revenue:	$1.42M
Gross Profit:	$1.42M (100.00%)
EPS:	$-0.460

Q1	2023
Revenue:	$2.25M
Gross Profit:	$2.25M (100.00%)
EPS:	$-0.550

Q4	2022
Revenue:	$18.18M
Gross Profit:	$18.18M (100.00%)
EPS:	$-0.420

NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Estimated
NGM Next Dividend
(Unknown) $0 Probabilty 0 %